Posted by Michael Wonder on 14 Feb 2022
Novavax files for conditional marketing authorisation of COVID-19 Vaccine in Switzerland
14 February 2022 - Novavax today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorisation of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant, for use in adults.
The submission for the regulatory evaluation by Swissmedic of NVX-CoV2373 includes data from two pivotal Phase 3 clinical trials: PREVENT-19, which enrolled approximately 30,000 participants aged 18 years and older in the U.S. and Mexico and was published in the New England Journal of Medicine and a trial with almost 15,000 adult participants in the U.K. which was also published in New England Journal of Medicine.
